{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:37:24Z","timestamp":1790735844651,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82202416"],"award-info":[{"award-number":["82202416"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the China Hepatitis Prevention and Control Foundation Mu Xin Chronic Hepatitis B Research Fund","award":["MX202409"],"award-info":[{"award-number":["MX202409"]}]},{"name":"the Beijing iGandan Foundation Clinical Research Project","award":["iGandanF-1082024-LG002"],"award-info":[{"award-number":["iGandanF-1082024-LG002"]}]},{"name":"the Qingdao Medical and Health Research Guidance Project","award":["2023-WJZD173"],"award-info":[{"award-number":["2023-WJZD173"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s40121-025-01212-4","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T15:53:36Z","timestamp":1756914816000},"page":"2373-2389","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and Safety of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide Fumarate in Treating Acute-on-Chronic Liver Failure with Hepatitis B Virus: A Network Meta-analysis"],"prefix":"10.1007","volume":"14","author":[{"given":"Jia","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanzhen","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefeng","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongning","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,3]]},"reference":[{"issue":"8","key":"1212_CR1","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s41575-023-00760-9","volume":"20","author":"YC Hsu","year":"2023","unstructured":"Hsu YC, Huang DQ, Nguyen MH. Global burden of hepatitis B virus: current status, missed opportunities and a call for action. Nat Rev Gastroenterol Hepatol. 2023;20(8):524\u201337. https:\/\/doi.org\/10.1038\/s41575-023-00760-9.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1212_CR2","unstructured":"World Health Organization. Global hepatitis report 2024: action for access in low-and middle-income countries. World Health Organization; 2024."},{"issue":"6","key":"1212_CR3","doi-asserted-by":"publisher","first-page":"e362","DOI":"10.1016\/s1473-3099(24)00307-4","volume":"24","author":"T Burki","year":"2024","unstructured":"Burki T. WHO\u2019s 2024 global hepatitis report. Lancet Infect Dis. 2024;24(6):e362\u20133. https:\/\/doi.org\/10.1016\/s1473-3099(24)00307-4.","journal-title":"Lancet Infect Dis"},{"key":"1212_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.752875","volume":"8","author":"A Khanam","year":"2021","unstructured":"Khanam A, Kottilil S. Acute-on-chronic liver failure: pathophysiological mechanisms and management. Front Med Lausanne. 2021;8: 752875. https:\/\/doi.org\/10.3389\/fmed.2021.752875.","journal-title":"Front Med Lausanne"},{"issue":"12","key":"1212_CR5","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1136\/gutjnl-2017-314641","volume":"67","author":"T Wu","year":"2018","unstructured":"Wu T, Li J, Shao L, et al. Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure. Gut. 2018;67(12):2181\u201391. https:\/\/doi.org\/10.1136\/gutjnl-2017-314641.","journal-title":"Gut"},{"key":"1212_CR6","doi-asserted-by":"publisher","unstructured":"Li F, Wang T, Tang F, Liang J. Fatal acute-on-chronic liver failure following camrelizumab for hepatocellular carcinoma with HBsAg seroclearance: a case report and literature review. Front Med. 2023;10:1231597. https:\/\/doi.org\/10.3389\/fmed.2023.1231597.","DOI":"10.3389\/fmed.2023.1231597"},{"issue":"7","key":"1212_CR7","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1080\/17474124.2022.2097070","volume":"16","author":"N Abbas","year":"2022","unstructured":"Abbas N, Rajoriya N, Elsharkawy AM, Chauhan A. Acute-on-chronic liver failure (ACLF) in 2022: have novel treatment paradigms already arrived? Expert Rev Gastroenterol Hepatol. 2022;16(7):639\u201352. https:\/\/doi.org\/10.1080\/17474124.2022.2097070.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"1212_CR8","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2147\/idr.S500291","volume":"18","author":"K Cui","year":"2025","unstructured":"Cui K, Liu CH, Teng X, et al. Association between artificial liver support system and prognosis in hepatitis B virus-related acute-on-chronic liver failure. Infect Drug Resist. 2025;18:113\u201326. https:\/\/doi.org\/10.2147\/idr.S500291.","journal-title":"Infect Drug Resist"},{"issue":"8","key":"1212_CR9","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1111\/apt.17659","volume":"58","author":"MF Butt","year":"2023","unstructured":"Butt MF, Jalan R. Review article: Emerging and current management of acute-on-chronic liver failure. Aliment Pharmacol Ther. 2023;58(8):774\u201394. https:\/\/doi.org\/10.1111\/apt.17659.","journal-title":"Aliment Pharmacol Ther"},{"key":"1212_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/cells11091410","author":"C Nikokiraki","year":"2022","unstructured":"Nikokiraki C, Psaraki A, Roubelakis MG. The potential clinical use of stem\/progenitor cells and organoids in liver diseases. Cells. 2022. https:\/\/doi.org\/10.3390\/cells11091410.","journal-title":"Cells"},{"issue":"4","key":"1212_CR11","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s12072-019-09946-3","volume":"13","author":"SK Sarin","year":"2019","unstructured":"Sarin SK, Choudhury A, Sharma MK, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update. Hepatol Int. 2019;13(4):353\u201390. https:\/\/doi.org\/10.1007\/s12072-019-09946-3.","journal-title":"Hepatol Int"},{"issue":"1","key":"1212_CR12","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"EASL Clinical Practice Guidelines","year":"2018","unstructured":"EASL Clinical Practice Guidelines. Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182\u2013236. https:\/\/doi.org\/10.1016\/j.jhep.2018.03.019.","journal-title":"J Hepatol"},{"issue":"1","key":"1212_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2023.08.008","volume":"14","author":"K Kumar","year":"2024","unstructured":"Kumar K, Jindal A, Gupta E, et al. Long-term HBsAg responses to Peg-interferon alpha-2b in HBeAg negative chronic hepatitis B patients developing clinical relapse after stopping long-term nucleos(t)ide analogue therapy. J Clin Exp Hepatol. 2024;14(1): 101272. https:\/\/doi.org\/10.1016\/j.jceh.2023.08.008.","journal-title":"J Clin Exp Hepatol"},{"issue":"1","key":"1212_CR14","doi-asserted-by":"publisher","first-page":"25286","DOI":"10.1038\/s41598-024-76270-8","volume":"14","author":"AS Ho","year":"2024","unstructured":"Ho AS, Chang J, Lee SD, et al. Nucleos(t)ide analogues potentially activate T lymphocytes through inducing interferon expression in hepatic cells and patients with chronic hepatitis B. Sci Rep. 2024;14(1):25286. https:\/\/doi.org\/10.1038\/s41598-024-76270-8.","journal-title":"Sci Rep"},{"key":"1212_CR15","doi-asserted-by":"publisher","unstructured":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines on acute-on-chronic liver failure. J Hepatol. 2023;79(2):461\u201391. https:\/\/doi.org\/10.1016\/j.jhep.2023.04.021.","DOI":"10.1016\/j.jhep.2023.04.021"},{"issue":"1","key":"1212_CR16","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1186\/s12876-023-03027-4","volume":"23","author":"Z Liu","year":"2023","unstructured":"Liu Z, Zhao Z, Ma X, Liu S, Xin Y. Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with hepatitis B: a network meta-analysis. BMC Gastroenterol. 2023;23(1):384. https:\/\/doi.org\/10.1186\/s12876-023-03027-4.","journal-title":"BMC Gastroenterol"},{"issue":"2","key":"1212_CR17","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1159\/000519440","volume":"65","author":"S Jeong","year":"2022","unstructured":"Jeong S, Shin HP, Kim HI. Real-world single-center comparison of the safety and efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in patients with chronic hepatitis B. Intervirology. 2022;65(2):94\u2013103. https:\/\/doi.org\/10.1159\/000519440.","journal-title":"Intervirology"},{"key":"1212_CR18","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00046-19","author":"MH Nguyen","year":"2020","unstructured":"Nguyen MH, Wong G, Gane E, Kao JH, Dusheiko G. Hepatitis B virus: advances in prevention, diagnosis, and therapy. Clin Microbiol Rev. 2020. https:\/\/doi.org\/10.1128\/cmr.00046-19.","journal-title":"Clin Microbiol Rev"},{"issue":"4","key":"1212_CR19","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.livres.2024.10.001","volume":"8","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Xu W, Deng Z, et al. Long-term efficacy and safety of tenofovir alafenamide, tenofovir disoproxil fumarate, and entecavir in treating hepatitis B virus-related acute-on-chronic liver failure: a 144-week data analysis. Liver Res. 2024;8(4):295\u2013303. https:\/\/doi.org\/10.1016\/j.livres.2024.10.001.","journal-title":"Liver Res"},{"key":"1212_CR20","doi-asserted-by":"publisher","unstructured":"Li Z, Zhu R, Dong J, Gao Y, Yan J. Short-term efficacy of tenofovir alafenamide in acute-on-chronic liver failure: a single-center experience. Clin Pathol (Thousand Oaks, Ventura County, Calif). 2024;17:2632010x241265858. https:\/\/doi.org\/10.1177\/2632010x241265858.","DOI":"10.1177\/2632010x241265858"},{"issue":"2","key":"1212_CR21","doi-asserted-by":"publisher","first-page":"194","DOI":"10.11817\/j.issn.1672-7347.2022.210578","volume":"47","author":"W Peng","year":"2022","unstructured":"Peng W, Gu H, Jiang C, Liu J, Zhang J, Fu L. Comparison of tenofovir alafenamide and entecavir for hepatitis B virus-related acute-on-chronic liver failure. Zhong nan da xue xue bao Yi xue ban\u00a0=\u00a0J Cent South Univ Med Sci. 2022;47(2):194\u2013201. https:\/\/doi.org\/10.11817\/j.issn.1672-7347.2022.210578.","journal-title":"Zhong nan da xue xue bao Yi xue ban\u00a0=\u00a0J Cent South Univ Med Sci."},{"issue":"7","key":"1212_CR22","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.4103\/jfmpc.jfmpc_2299_20","volume":"10","author":"SMS Hossain","year":"2021","unstructured":"Hossain SMS, Mahtab MA, Das DC, et al. Comparative role of tenofovir versus entecavir for treating patients with hepatitis B virus-related acute-on-chronic liver failure. J Family Med Prim Care. 2021;10(7):2642\u20135. https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_2299_20.","journal-title":"J Family Med Prim Care"},{"key":"1212_CR23","doi-asserted-by":"publisher","first-page":"5728359","DOI":"10.1155\/2020\/5728359","volume":"2020","author":"K Zhang","year":"2020","unstructured":"Zhang K, Lin S, Wang M, Huang J, Zhu Y. The risk of acute kidney injury in hepatitis B virus-related acute-on-chronic liver failure with tenofovir treatment. BioMed Res Int. 2020;2020:5728359. https:\/\/doi.org\/10.1155\/2020\/5728359.","journal-title":"BioMed Res Int"},{"key":"1212_CR24","doi-asserted-by":"publisher","DOI":"10.4178\/epih.e2017047","volume":"39","author":"S Shim","year":"2017","unstructured":"Shim S, Yoon BH, Shin IS, Bae JM. Network meta-analysis: application and practice using Stata. Epidemiol Health. 2017;39: e2017047. https:\/\/doi.org\/10.4178\/epih.e2017047.","journal-title":"Epidemiol Health"},{"issue":"4","key":"1212_CR25","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1002\/jrsm.1270","volume":"8","author":"G R\u00fccker","year":"2017","unstructured":"R\u00fccker G, Schwarzer G. Resolve conflicting rankings of outcomes in network meta-analysis: partial ordering of treatments. Res Synth Methods. 2017;8(4):526\u201336. https:\/\/doi.org\/10.1002\/jrsm.1270.","journal-title":"Res Synth Methods"},{"key":"1212_CR26","doi-asserted-by":"publisher","first-page":"1185492","DOI":"10.3389\/fmicb.2023.1185492","volume":"14","author":"W Peng","year":"2023","unstructured":"Peng W, Gu H, Cheng D, et al. Tenofovir alafenamide versus entecavir for treating hepatitis B virus-related acute-on-chronic liver failure: real-world study. Front Microbiol. 2023;14:1185492. https:\/\/doi.org\/10.3389\/fmicb.2023.1185492.","journal-title":"Front Microbiol"},{"issue":"4","key":"1212_CR27","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1111\/jvh.13468","volume":"28","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Xu W, Zhu X, et al. The 48-week safety and therapeutic effects of tenofovir alafenamide in HBV-related acute-on-chronic liver failure: a prospective cohort study. J Viral Hepat. 2021;28(4):592\u2013600. https:\/\/doi.org\/10.1111\/jvh.13468.","journal-title":"J Viral Hepat"},{"issue":"1","key":"1212_CR28","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1186\/s12879-021-06237-x","volume":"21","author":"J Li","year":"2021","unstructured":"Li J, Hu C, Chen Y, et al. Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B. BMC Infect Dis. 2021;21(1):567. https:\/\/doi.org\/10.1186\/s12879-021-06237-x.","journal-title":"BMC Infect Dis"},{"issue":"4","key":"1212_CR29","doi-asserted-by":"publisher","first-page":"e171","DOI":"10.1097\/mcg.0000000000001038","volume":"53","author":"YM Wan","year":"2019","unstructured":"Wan YM, Li YH, Xu ZY, et al. Tenofovir versus entecavir for the treatment of acute-on-chronic liver failure due to reactivation of chronic hepatitis B with genotypes B and C. J Clin Gastroenterol. 2019;53(4):e171\u20137. https:\/\/doi.org\/10.1097\/mcg.0000000000001038.","journal-title":"J Clin Gastroenterol"},{"key":"1212_CR30","doi-asserted-by":"publisher","unstructured":"Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for diagnosis and treatment of liver failure (2024 version). Zhonghua Gan Zang Bing Za Zhi. 2025;33(1):18\u201333. https:\/\/doi.org\/10.3760\/cma.j.cn501113-20241206-00614.","DOI":"10.3760\/cma.j.cn501113-20241206-00614"},{"key":"1212_CR31","doi-asserted-by":"publisher","unstructured":"Wang N, He S, Zheng Y, Wang L. Efficacy and safety of tenofovir disoproxil fumarate versus entecavir in the treatment of acute-on-chronic liver failure with hepatitis B: a systematic review and meta-analysis. BMC Gastroenterol. 2023;23(1):388. https:\/\/doi.org\/10.1186\/s12876-023-03024-7.","DOI":"10.1186\/s12876-023-03024-7"},{"issue":"5","key":"1212_CR32","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.amjms.2017.03.005","volume":"353","author":"W Yuan","year":"2017","unstructured":"Yuan W, Zhang YY, Zhang ZG, Zou Y, Lu HZ, Qian ZP. Risk factors and outcomes of acute kidney injury in patients with hepatitis B virus-related acute-on-chronic liver failure. Am J Med Sci. 2017;353(5):452\u20138. https:\/\/doi.org\/10.1016\/j.amjms.2017.03.005.","journal-title":"Am J Med Sci"},{"issue":"Suppl 1","key":"1212_CR33","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/liv.13641","volume":"38","author":"M Buti","year":"2018","unstructured":"Buti M, Riveiro-Barciela M, Esteban R. Long-term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B. Liver Int: Off J Int Assoc Study Liver. 2018;38(Suppl 1):84\u20139. https:\/\/doi.org\/10.1111\/liv.13641.","journal-title":"Liver Int: Off J Int Assoc Study Liver"},{"issue":"3","key":"1212_CR34","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/jgh.12499","volume":"29","author":"J Fung","year":"2014","unstructured":"Fung J, Seto WK, Lai CL, Yuen MF. Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment. J Gastroenterol Hepatol. 2014;29(3):428\u201334. https:\/\/doi.org\/10.1111\/jgh.12499.","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"1212_CR35","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12981-021-00380-w","volume":"18","author":"T Ueaphongsukkit","year":"2021","unstructured":"Ueaphongsukkit T, Gatechompol S, Avihingsanon A, et al. Tenofovir alafenamide nephrotoxicity: a case report and literature review. AIDS Res Ther. 2021;18(1):53. https:\/\/doi.org\/10.1186\/s12981-021-00380-w.","journal-title":"AIDS Res Ther"},{"issue":"7","key":"1212_CR36","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1080\/17512433.2017.1323633","volume":"10","author":"S Abdul Basit","year":"2017","unstructured":"Abdul Basit S, Dawood A, Ryan J, Gish R. Tenofovir alafenamide for the treatment of chronic hepatitis B virus infection. Expert Rev Clin Pharmacol. 2017;10(7):707\u201316. https:\/\/doi.org\/10.1080\/17512433.2017.1323633.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1212_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bcp.2016.04.015","volume":"119","author":"E De Clercq","year":"2016","unstructured":"De Clercq E. Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF). Biochem Pharmacol. 2016;119:1\u20137. https:\/\/doi.org\/10.1016\/j.bcp.2016.04.015.","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"1212_CR38","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","volume":"68","author":"K Agarwal","year":"2018","unstructured":"Agarwal K, Brunetto M, Seto WK, et al. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol. 2018;68(4):672\u201381. https:\/\/doi.org\/10.1016\/j.jhep.2017.11.039.","journal-title":"J Hepatol"},{"issue":"3","key":"1212_CR39","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/s2468-1253(16)30107-8","volume":"1","author":"M Buti","year":"2016","unstructured":"Buti M, Gane E, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1(3):196\u2013206. https:\/\/doi.org\/10.1016\/s2468-1253(16)30107-8.","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-025-01212-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-025-01212-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-025-01212-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T09:27:26Z","timestamp":1759138046000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-025-01212-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,3]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1212"],"URL":"https:\/\/doi.org\/10.1007\/s40121-025-01212-4","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,3]]},"assertion":[{"value":"13 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jia Liu, Yanzhen Bi, Xuefeng Ma and Yongning Xin declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}